NCT05907395 - A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions

Healthy Participants

Interventions

DRUG

PF-07293893

PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.

DRUG

Placebo

Matching placebo will be prepared as an oral suspension given in each cohort.

Trial Locations (1)

Pfizer Clinical Research Unit - Brussels, Brussels